Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pelitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 14/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pelitinib SCHEMBL29623744 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29385637 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29352012 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29349785 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL93757 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL8132957 | 0.93 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL6382792 | 0.93 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL12641715 | 0.92 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL10108217 | 0.92 | EGFR (0.85) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL14944414 | 0.92 | EGFR (0.85) | EGFRERBB2STK25CITCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1832 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | claimed |
| US-20230149415-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-05-18 | — | — | US | claimed |
| EP-4127722-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Engine Biosciences Pte. Ltd. (SG) | 2023-02-08 | — | — | EP | claimed |
| US-20220356494-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-11-10 | — | — | US | claimed |
| EP-4077690-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Engine Biosciences Pte. Ltd. (SG) | 2022-10-26 | — | — | EP | claimed |
| WO-2021202780-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2021-10-07 | — | — | WO | claimed |
| WO-2021126995-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2021-06-24 | — | — | WO | claimed |
| WO-2016079332-A1 | GEL FORMULATIONS FOR IMPROVING IMMUNOTHERAPY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2016-05-26 | — | — | WO | claimed |
| CN-104703588-A | Cationic liposome delivery system for specific targeting of human CD14+ monocytes in whole blood | BIONEER AS | 2015-06-10 | — | — | CN | claimed |
| US-9006240-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-14 | — | — | US | claimed |
| EP-1472213-A1 | PROCESS FOR THE SYNTHESIS OF N-ACYL-2-AMINO-4-ALKOXY-5-NITROBENZOIC ACIDS | Wyeth (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2004035057-A1 | THERAPEUTIC TREATMENT | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | WO | claimed |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| WO-2004004775-A1 | NOVEL DRUG COMPOSITIONS BASED ON NOVEL ANTICHOLINERGICS AND INHIBITORS OF EGFR-KINASE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | claimed |
| WO-2003094921-A2 | UTILIZATION OF INHIBITORS OF EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)/PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-20 | — | — | WO | claimed |
| US-20030158196-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-08-21 | — | — | US | claimed |
| WO-2003066575-A1 | PROCESS FOR THE SYNTHESIS OF N-ACYL-2-AMINO-4-ALKOXY-5-NITROBENZOIC ACIDS | WYETH (US) | 2003-08-14 | — | — | WO | claimed |
| WO-2003066060-A2 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-08-14 | — | — | WO | claimed |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-08-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356494-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SRC, BCOR, CTTN | EGFR 491/4885ERBB2 114/4885STK25 967/4885 |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885STK25 95/4885 |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BPHL, EGFR, ERBB3 | EGFR 2/4885ERBB2 4/4885STK25 557/4885 |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | CHRM3, EGFR, ERBB2 | EGFR 2/4885ERBB2 3/4885STK25 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.